GHRP-2 Acetate, also widely known as Pralmorelin or KP-102, is a synthetic six-amino-acid hexapeptide classified as a potent growth hormone secretagogue (GHS). It functions as a selective agonist targeting the GHS-R1a ghrelin receptor, which is expressed abundantly on anterior pituitary gland cells, hypothalamic neurons and multiple peripheral tissues. The peptide incorporates multiple D-configured amino acid residues and C-terminal amidation modification. These structural optimizations greatly enhance resistance against endogenous peptidase degradation compared with natural L-peptides, which is the core reason for its stable biological activity in preclinical laboratory models. The acetate salt counterion is selected specifically to improve aqueous solubility, reduce peptide aggregation during lyophilization and reconstitution, and stabilize the peptide backbone during long-term cold storage.

Different from GHRH (growth hormone-releasing hormone) analogs that trigger GH release through separate receptor pathways, GHRP-2 activates GHS-R1a to induce pulsatile secretion of growth hormone from pituitary somatotrophs. Importantly, its signaling pathway is independent of GHRH, which enables synergistic biological effects when combined with GHRH derivatives such as CJC-1295 in research experiments. Compared with other classic GHRP family peptides like GHRP-6, GHRP-2 demonstrates higher potency for stimulating GH release while exhibiting weaker appetite-stimulating effects and milder secondary elevation of cortisol and prolactin, providing researchers with a more selective tool for endocrinology studies.

Beyond pituitary GH secretion research, GHRP-2 Acetate is widely adopted across multiple preclinical research directions. It is frequently applied to explore ghrelin receptor signaling cascades, somatotroph cell function, IGF-1 downstream expression, metabolic regulation, cardiac tissue protection and inflammatory response modulation. Researchers also use this peptide to build in vitro and in vivo models for investigating hormone deficiency, energy metabolism balance, and the crosstalk between neuroendocrine and immune systems. Its short plasma half-life of roughly 20–30 minutes in animal models makes it ideal for studying pulsatile hormone release patterns, which closely mimic the physiological rhythm of endogenous hormone secretion.

Our GHRP-2 Acetate is manufactured by solid-phase peptide synthesis technology. The peptide chain is assembled residue by residue, followed by cleavage, deprotection and salt conversion to form acetate salt. Crude peptide undergoes repeated preparative reversed-phase HPLC purification to remove truncated fragments, deletion sequences, residual protecting groups and organic impurities. Each batch undergoes comprehensive quality control workflow, including HPLC purity detection, mass spectrometry molecular identity confirmation, amino acid composition analysis, moisture testing and visual appearance inspection. Complete COA, HPLC chromatogram and mass spectrum documents can be provided for each shipment to satisfy strict laboratory audit and record-keeping requirements. Lyophilization is implemented to lock molecular conformation, minimizing peptide degradation risk during international shipment and long-term frozen preservation. This product is supplied to university laboratories, biotech R&D institutes and pharmaceutical preclinical research teams for pituitary endocrinology experiments, ghrelin receptor mechanism research, growth hormone pathway study, metabolic physiology and peptide ligand screening projects.